TargeGen Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: San Diego CA United States (2002)
Status: Acquired by Sanofi-Aventis (2010)

Organization Overview

First Clinical Trial
2005
NCT00103350
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

tg100 (1 trial)

tg-100801 (2 trials)

Drugs in Phase 1 Trials (1)

fedratinib (Inrebic) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 2)

Diabetic Retinopathy (Phase 1)

Infarction (Phase 2)

Macular Degeneration (Phase 2)

Myocardial Infarction (Phase 2)

Neovascularization, Pathologic (Phase 2)

Polycythemia Vera (Phase 1)

Primary Myelofibrosis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3